Complement activation products in the circulation and urine of primary membranous nephropathy

BMC Nephrology

Zhao Cui¹  Li-qiang Meng¹  Jing Huang¹  Xin Wang¹  Zhen Qu¹  Mu-fan Zhang¹  Xu-yang Cheng¹  Fang Wang¹  Gang Liu¹  Yi-miao Zhang¹  Ming-hui Zhao¹ 

[1] Department of Medicine, Renal Division, Peking University First Hospital;

关键词: Primary membranous nephropathy;    Complement;    C3a;    C5a;    PLA2R;   

DOI  :  10.1186/s12882-019-1509-5

来源: DOAJ

【 摘 要 】

Abstract Background Complement activation plays a substantial role in the pathogenesis of primary membranous nephropathy (pMN). C5b-9, C3c, MBL, and factor B have been documented in the subepithelial immune deposits. However, the changing of complement activation products in circulation and urine is not clear. Methods We measured the circulating and urinary levels of C1q, MBL, C4d, Bb, properdin, C3a, C5a, and sC5b-9, in 134 patients with biopsy-proven pMN, by enzyme-linked immunosorbent assay. All the plasma values were corrected by eGFR and all the urinary values were corrected by urinary creatinine and urinary protein excretion. Anti-PLA2R antibodies were measured in all patients. Results The plasma complement activation products were elevated both in the patients with and without anti-PLA2R antibodies. C3a levels were remarkably increased in the circulation and urine, much higher than the elevated levels of C5a. C5b-9 was in normal range in plasma, but significantly higher in urine. The urinary C5a had a positive correlation with anti-PLA2R antibody levels and urinary protein. The plasma level of C4d was elevated, but C1q and MBL were comparable to healthy controls. Positive correlations were observed between plasma C4d/MBL and urinary protein, only in the patients with positive anti-PLA2R antibodies but not in those without. The plasma level of Bb was elevated and had positive correlation with urinary protein only in the patients without anti-PLA2R antibodies. Conclusion Complement activation products were remarkable increased in pMN and may serve as sensitive biomarkers of disease activity. The complement may be activated through lectin pathway with the existence of anti-PLA2R antibodies, while through alternative pathway in the absence of antibody.

【 授权许可】

Unknown